메뉴 건너뛰기




Volumn 392, Issue 10157, 2018, Pages 1519-1529

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

(795)  Hernandez, Adrian F a,h   Green, Jennifer B a,h   Janmohamed, Salim b,h   D'Agostino, Ralph B c,h   Granger, Christopher B a,h   Jones, Nigel P b,h   Leiter, Lawrence A d,h   Rosenberg, Anne E a,h   Sigmon, Kristina N a,h   Somerville, Matthew C e,h   Thorpe, Karl M b,h   McMurray, John J V f,h   Del Prato, Stefano g,h   Califf, Robert M h   Holman, Rury h   DeMets, David h   Riddle, Matthew h   Goodman, Shaun h   McGuire, Darren h   Alexander, Karen h   more..

h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBIGLUTIDE; BILIRUBIN; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; RGLP-1 PROTEIN;

EID: 85055101508     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)32261-X     Document Type: Article
Times cited : (1214)

References (23)
  • 1
    • 85018394748 scopus 로고    scopus 로고
    • Mortality and cardiovascular disease in type 1 and type 2 diabetes
    • Rawshani, A, Rawshani, A, Franzén, S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 376 (2017), 1407–1418.
    • (2017) N Engl J Med , vol.376 , pp. 1407-1418
    • Rawshani, A.1    Rawshani, A.2    Franzén, S.3
  • 2
    • 79952260576 scopus 로고    scopus 로고
    • Diabetes mellitus, fasting glucose, and risk of cause-specific death
    • Rao Kondapally Seshasai, S, Kaptoge, S, Thompson, A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364 (2011), 829–841.
    • (2011) N Engl J Med , vol.364 , pp. 829-841
    • Rao Kondapally Seshasai, S.1    Kaptoge, S.2    Thompson, A.3
  • 3
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 4
    • 85034766786 scopus 로고    scopus 로고
    • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • Neal, B, Perkovic, V, Mahaffey, KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
    • (2017) N Engl J Med , vol.377 , pp. 644-657
    • Neal, B.1    Perkovic, V.2    Mahaffey, K.W.3
  • 5
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
    • (2016) N Engl J Med , vol.375 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 6
    • 84994813253 scopus 로고    scopus 로고
    • Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
    • Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
    • (2016) N Engl J Med , vol.375 , pp. 1834-1844
    • Marso, S.P.1    Bain, S.C.2    Consoli, A.3
  • 7
    • 84948740668 scopus 로고    scopus 로고
    • Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
    • Pfeffer, MA, Claggett, B, Diaz, R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
    • (2015) N Engl J Med , vol.373 , pp. 2247-2257
    • Pfeffer, M.A.1    Claggett, B.2    Diaz, R.3
  • 8
    • 85030448557 scopus 로고    scopus 로고
    • Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
    • Holman, RR, Bethel, MA, Mentz, RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
    • (2017) N Engl J Med , vol.377 , pp. 1228-1239
    • Holman, R.R.1    Bethel, M.A.2    Mentz, R.J.3
  • 9
    • 84976260652 scopus 로고    scopus 로고
    • Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
    • Tahrani, AA, Barnett, AH, Bailey, CJ, Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12 (2016), 566–592.
    • (2016) Nat Rev Endocrinol , vol.12 , pp. 566-592
    • Tahrani, A.A.1    Barnett, A.H.2    Bailey, C.J.3
  • 11
    • 85049515756 scopus 로고    scopus 로고
    • Harmony Outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—rationale, design, and baseline characteristics
    • Green, JB, Hernandez, AF, D'Agostino, RB, et al. Harmony Outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—rationale, design, and baseline characteristics. Am Heart J 203 (2018), 30–38.
    • (2018) Am Heart J , vol.203 , pp. 30-38
    • Green, J.B.1    Hernandez, A.F.2    D'Agostino, R.B.3
  • 12
    • 85048054697 scopus 로고    scopus 로고
    • Multiplicity considerations in clinical trials
    • Dmitrienko, A, D'Agostino, RB Sr, Multiplicity considerations in clinical trials. N Engl J Med 378 (2018), 2115–2122.
    • (2018) N Engl J Med , vol.378 , pp. 2115-2122
    • Dmitrienko, A.1    D'Agostino, R.B.2
  • 13
    • 84990876868 scopus 로고    scopus 로고
    • Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
    • (Accessed 22 September 2018)
    • US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf, December, 2008. (Accessed 22 September 2018)
    • (2008)
  • 14
    • 85044966014 scopus 로고    scopus 로고
    • Noninferiority trials
    • Mauri, L, D'Agostino, RB Sr, Noninferiority trials. N Engl J Med 378 (2018), 304–305.
    • (2018) N Engl J Med , vol.378 , pp. 304-305
    • Mauri, L.1    D'Agostino, R.B.2
  • 15
    • 0000336139 scopus 로고
    • Regression models and life tables
    • Cox, DR, Regression models and life tables. J Royal Stat Soc 34 (1972), 187–220.
    • (1972) J Royal Stat Soc , vol.34 , pp. 187-220
    • Cox, D.R.1
  • 16
    • 85052152433 scopus 로고    scopus 로고
    • Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
    • Boyle, JG, Livingstone, R, Petrie, JR, Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Clin Sci 132 (2018), 1699–1709.
    • (2018) Clin Sci , vol.132 , pp. 1699-1709
    • Boyle, J.G.1    Livingstone, R.2    Petrie, J.R.3
  • 17
    • 85044600598 scopus 로고    scopus 로고
    • Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
    • Bethel, MA, Patel, RA, Merrill, P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6 (2018), 105–113.
    • (2018) Lancet Diabetes Endocrinol , vol.6 , pp. 105-113
    • Bethel, M.A.1    Patel, R.A.2    Merrill, P.3
  • 19
    • 85047739558 scopus 로고    scopus 로고
    • GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms
    • Rizzo, M, Nikolic, D, Patti, AM, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms. Biochim Biophys Acta 1864 (2018), 2814–2821.
    • (2018) Biochim Biophys Acta , vol.1864 , pp. 2814-2821
    • Rizzo, M.1    Nikolic, D.2    Patti, A.M.3
  • 20
    • 85041694897 scopus 로고    scopus 로고
    • Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
    • Vilsbøll, T, Bain, SC, Leiter, LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20 (2018), 889–897.
    • (2018) Diabetes Obes Metab , vol.20 , pp. 889-897
    • Vilsbøll, T.1    Bain, S.C.2    Leiter, L.A.3
  • 21
    • 85025113297 scopus 로고    scopus 로고
    • Efficacy and safety of GLP-1 receptor agonists across the spectrum of type 2 diabetes mellitus
    • Leiter, LA, Nauck, MA, Efficacy and safety of GLP-1 receptor agonists across the spectrum of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 125 (2017), 419–435.
    • (2017) Exp Clin Endocrinol Diabetes , vol.125 , pp. 419-435
    • Leiter, L.A.1    Nauck, M.A.2
  • 23
    • 85056236437 scopus 로고    scopus 로고
    • Use of GLP-1 RAs in cardiovascular disease prevention: a practical guide
    • Lingvay, I, Leiter, LA, Use of GLP-1 RAs in cardiovascular disease prevention: a practical guide. Circulation 137 (2018), 2200–2202.
    • (2018) Circulation , vol.137 , pp. 2200-2202
    • Lingvay, I.1    Leiter, L.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.